Antigonie Biosciences Overview

  • Year Founded
  • 2025

Year Founded

  • Status
  • Private

  • Employees
  • 3

Employees

  • Latest Deal Type
  • Accelerator/​Inc

  • Investors
  • 2

Antigonie Biosciences General Information

Description

Developer of a gene therapy platform designed to eliminate malignant blood-forming stem cells through selective mutation silencing. The company's platform targets specific mutations within hematopoietic stem cells while preserving healthy tissues, enabling researchers to transition patients from lifelong disease management to curative medical strategies.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Accelerator/Incubator Backed
Corporate Office
  • Centre For Blood Research, University Of York
  • York YO10 5DD
  • England, United Kingdom
Primary Industry
Drug Delivery
Other Industries
Other Healthcare Technology Systems
Biotechnology
Corporate Office
  • Centre For Blood Research, University Of York
  • York YO10 5DD
  • England, United Kingdom

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Antigonie Biosciences Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Accelerator/Incubator 08-Jun-2026 Completed Pre-Clinical Trials
1. Accelerator/Incubator Completed Pre-Clinical Trials
To view Antigonie Biosciences’s complete valuation and funding history, request access »

Antigonie Biosciences Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Antigonie Biosciences Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds
Pxn Ventures Corporate Venture Capital Minority
Cancer Tech Accelerator Accelerator/Incubator
To view Antigonie Biosciences’s complete investors history, request access »

Antigonie Biosciences FAQs

  • When was Antigonie Biosciences founded?

    Antigonie Biosciences was founded in 2025.

  • Where is Antigonie Biosciences headquartered?

    Antigonie Biosciences is headquartered in York, United Kingdom.

  • What is the size of Antigonie Biosciences?

    Antigonie Biosciences has 3 total employees.

  • What industry is Antigonie Biosciences in?

    Antigonie Biosciences’s primary industry is Drug Delivery.

  • Is Antigonie Biosciences a private or public company?

    Antigonie Biosciences is a Private company.

  • What is Antigonie Biosciences’s current revenue?

    The current revenue for Antigonie Biosciences is .

  • Who are Antigonie Biosciences’s investors?

    Pxn Ventures and Cancer Tech Accelerator have invested in Antigonie Biosciences.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process